Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea.

[1]  Jeremy Nathans,et al.  Macular degeneration: recent advances and therapeutic opportunities , 2006, Nature Reviews Neuroscience.

[2]  Hongliang Lan,et al.  Design and mechanism of action of a novel bacteria-selective antimicrobial peptide from the cell-penetrating peptide Pep-1. , 2006, Biochemical and biophysical research communications.

[3]  R. Avery,et al.  Ranibizumab: treatment in patients with neovascular age-related macular degeneration , 2006, Expert opinion on biological therapy.

[4]  M. Hällbrink,et al.  Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects , 2006, Peptides.

[5]  K. Hahm,et al.  Biological activity of Tat (47-58) peptide on human pathogenic fungi. , 2006, Biochemical and biophysical research communications.

[6]  P. Rosenfeld,et al.  Promising new treatments for neovascular age-related macular degeneration , 2006, Expert opinion on investigational drugs.

[7]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[8]  S Louise Moffatt,et al.  Centennial review of corneal transplantation , 2005, Clinical & experimental ophthalmology.

[9]  Gunnar P. H. Dietz,et al.  Delivery of bioactive molecules into the cell: the Trojan horse approach , 2004, Molecular and Cellular Neuroscience.

[10]  E. Check.  Firm sets sights on gene silencing to protect vision , 2004, Nature.

[11]  D. Morris,et al.  Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  S. Eykyn,et al.  Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. , 2003, Survey of ophthalmology.

[13]  J. Frederick,et al.  Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors--implications for gene therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  A. Balestrazzi,et al.  Escherichia Coli Endophthalmitis after Trans-Scleral Resection of Uveal Melanoma , 2002, European journal of ophthalmology.

[15]  M. Johansson,et al.  Is VP22 nuclear homing an artifact? , 2001, Nature Biotechnology.

[16]  J. Wesche,et al.  Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. , 2001, Biochemistry.

[17]  M. Germann,et al.  Design of Peptides with High Affinities for Heparin and Endothelial Cell Proteoglycans* , 2000, The Journal of Biological Chemistry.

[18]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[19]  A. Phelan,et al.  Intercellular delivery of functional p53 by the herpesvirus protein VP22 , 1998, Nature Biotechnology.

[20]  D. Hicks,et al.  Acidic and basic fibroblast growth factor messenger RNA and protein show increased expression in adult compared to developing normal and dystrophic rat retina , 1997, Journal of Molecular Neuroscience.

[21]  G. Olivecrona,et al.  Ligand binding to heparan sulfate proteoglycans induces their aggregation and distribution along actin cytoskeleton. , 1996, Molecular biology of the cell.

[22]  A. Houweling,et al.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. , 1996, Human gene therapy.

[23]  J. Hollyfield,et al.  Increased Retinal Synthesis of Heparan Sulfate Proteoglycan and HNK‐1 Glycoproteins Following Photoreceptor Degeneration , 1994, Journal of neurochemistry.

[24]  A. Prochiantz,et al.  The third helix of the Antennapedia homeodomain translocates through biological membranes. , 1994, The Journal of biological chemistry.

[25]  A. Cardin,et al.  Molecular Modeling of Protein‐Glycosaminoglycan Interactions , 1989, Arteriosclerosis.

[26]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[27]  J W Shell,et al.  Ophthalmic drug delivery systems , 1984, Survey of ophthalmology.

[28]  Retinitis pigmentosa,et al.  RETINITIS PIGMENTOSA , 1941, The Lancet.

[29]  J. Loewenstein,et al.  Endophthalmitis Associated With Intravitreal Injections , 2007, International ophthalmology clinics.

[30]  E. Vivés,et al.  Cell-penetrating Peptides A REEVALUATION OF THE MECHANISM OF CELLULAR UPTAKE* , 2002 .